KEY POINTS FROM CNBC
- Alzheimer’s patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai shows.
- The analysis found Alzheimer’s disease continued to progress slower in patients who took Leqembi even when they were off the treatment for an average of two years.
- The findings come as the Japanese drugmaker and its partner Biogen await a decision on full approval of Leqembi.
Read more at CNBC
